PlainRecalls
FDA Drug Low Class III Terminated

Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.

Reported: October 24, 2018 Initiated: October 5, 2018 #D-0249-2019

Product Description

Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.

Reason for Recall

Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.

Details

Units Affected
5,232 bottles: a) 4,146 bottles; b) 1,086 bottles
Distribution
Product was distributed U.S. nationwide.
Location
Lyndhurst, NJ

Frequently Asked Questions

What product was recalled?
Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.. Recalled by Amerigen Pharmaceuticals Inc.. Units affected: 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles.
Why was this product recalled?
Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 24, 2018. Severity: Low. Recall number: D-0249-2019.